1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
Real-time Euronext Paris  -  11:38 2022-08-12 am EDT
1.350 EUR   +4.65%
08/11European ADRs Move Lower in Thursday Trading
MT
08/09European ADRs Move Higher in Tuesday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Report – ERYTECH's Combined Shareholders' Meeting On June 24, 2022

06/24/2022 | 04:05pm EDT

REPORT ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022

Cambridge, MA (U.S.) and Lyon (France), June 24, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Annual General Meeting was held on Friday, June 24, 2022.

At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including:

  • Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;
  • Allocation of the financial year's results;
  • Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;
  • Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;
  • Approval of the compensation policy for executive corporate officers and Board members;
  • Renewal of the term of office as Director of:
    • Jean-Paul KRESS
    • Gil BEYEN
    • Philippe ARCHINARD
    • Luc DOCHEZ
    • Sven ANDRÉASSON following the ratification of his appointment by cooptation
  • Renewal of the mandate of KPMG SA as joint statutory auditor;
  • Approval of the share subscription and/or purchase options plan adopted by the Board of Directors on July 27, 2021;
  • Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders;
  • Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group.

The full results of all matters voted on at the meeting will be made available on the Company’s website at www.erytech.com, within the Shareholders Meeting/2022 section under the Investors tab.

About ERYTECH and eryaspase (GRASPA®) www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in the United States and potentially other territories. The Company is also pursuing a Phase 1 investigator-sponsored clinical trial in first-line pancreatic cancer.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL. Eryaspase is not an approved medicine.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and expects to be able to produce for patients in the United States through an anticipated long-term supply agreement with Catalent, operating from ERYTECH’s former GMP facility in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

CONTACTS

ERYTECH                     

Eric Soyer

CFO & COO
NewCap

Mathilde Bohin / Louis-Victor Delouvrier

Investor relations

Nicolas Merigeau

Media relations


+33 4 78 74 44 38

investors@erytech.com


+33 1 44 71 94 94

erytech@newcap.eu

Attachment


Primary Logo

Source: Erytech Pharma S.A.

2022 GlobeNewswire, Inc., source Press Releases

All news about ERYTECH PHARMA S.A.
08/11European ADRs Move Lower in Thursday Trading
MT
08/09European ADRs Move Higher in Tuesday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
08/04European ADRs Move Higher in Thursday Trading
MT
08/03European ADRs Nudge Higher in Wednesday Trading
MT
07/28European ADRs Decline in Thursday Trading
MT
07/22European ADRs Edge Higher in Friday Trading
MT
07/13European ADRs Move Higher in Wednesday Trading
MT
07/11European ADRs Move Lower in Monday Trading
MT
07/07European ADRs Move Higher in Thursday Trading
MT
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2022 9,20 M 9,43 M 9,43 M
Net income 2022 -52,8 M -54,1 M -54,1 M
Net Debt 2022 1,50 M 1,54 M 1,54 M
P/E ratio 2022 -0,61x
Yield 2022 -
Capitalization 41,9 M 42,9 M 42,9 M
EV / Sales 2022 4,71x
EV / Sales 2023 2,53x
Nbr of Employees 181
Free-Float 98,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 1,35 €
Average target price 3,60 €
Spread / Average Target 167%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-36.32%43
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968